Hyloris Announces Annual General Meeting of Shareholders on 8 June 2021


Liège, Belgium – 7 May 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today informs its shareholders and warrant holders that the Company’s Annual General Meeting of Shareholders will be held on Tuesday 8 June 2021 at 2:00 pm CEST at its registered offices, Boulevard Gustave-Kleyer 17, 4000 Liège, Belgium.

Due to the COVID-19 pandemic and the measures imposed by the Belgian government to deal with this pandemic, including the prohibition to organise large-scale, in-person gatherings, which may still be in effect on the date of the Company's Annual General Shareholders’ Meeting, it has been decided to hold the Meeting behind closed doors.  

As such, the Company will set up a videoconference to allow shareholders and warrant holders who have duly registered for the Meeting to follow the Meeting remotely. The videoconference does not qualify as an electronic voting tool or a platform to ask questions. The Company therefore invites its shareholders and warrant holders to exercise their right to vote through voting by letter ahead of the meeting or by means of a written proxy. Questions can be asked in writing in advance of the Meeting.

More information about voting by letter or by written proxy and exercising the right to ask questions can be found in the convening notice.

The annual report 2020, the convening notice, forms and other documents relating to the general shareholders’ meeting can be consulted on the Company’s website. It is recommended to use email for all communication with the Company regarding the Annual General Meeting of Shareholders via corporate@hyloris.com.

About Hyloris Pharmaceuticals
Hyloris is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris currently has two partnered, commercial-stage products: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn

For more information, please contact Hyloris Pharmaceuticals:
Marieke Vermeersch

VP Investor Relations and Corporate Communications
M: +32 (0)479 490 603

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.